The Lancet

Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions

Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...

New AI system provides treatment recommendations for complex blood cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute and Heidelberg University ...
The Lancet

The PERC-Peds rule: a promising step towards structured pulmonary embolism risk assessment in children

Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
Las Vegas Sun

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...
Targeted Oncology

Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera

Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course. During a ...
The American Journal of Managed Care

The Future of Factor XIa Inhibition: Clinical Integration and Treatment Algorithms

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal. In this installment of this series, ‘The Future of Factor XIa ...
Frontiers

Tracing the Evolution of Mechanical Advanced Treatment from Pharmaco-Invasive Therapies to Endovascular Thrombectomy in Pulmonary Embolism Management

You will be redirected to our submission process. Pulmonary embolism (PE) presents significant risks when escalating to a high-risk state, demanding immediate and effective intervention. Over the ...
ahajournals.org

2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of ...

A new clinical classification scheme is presented, entitled “Acute Pulmonary Embolism Clinical Categories,” with 5 categories (A-E) and subcategories, ranging from low to high risk for adverse ...
Business Wire

OpenEvidence Collaborates With NCCN to Integrate Canonical Oncology Treatment Algorithms at the Point-of-Care

MIAMI--(BUSINESS WIRE)--OpenEvidence now integrates National Comprehensive Cancer Network ® (NCCN ®) Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) directly in answers, grounding ...
Morningstar

OpenEvidence Collaborates With NCCN to Integrate Canonical Oncology Treatment Algorithms at the Point-of-Care

OpenEvidence now integrates National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) directly in answers, grounding responses in the pinnacle ...